医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ABEC 4,000 Liter Single-Use Bioreactor to Expand Emergent BioSolutions Manufacturing Capability

2017年10月24日 PM10:32
このエントリーをはてなブックマークに追加


 

BETHLEHEM, Pa.

ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced that Emergent BioSolutions will equip their Baltimore, Maryland bulk manufacturing facility (Bayview), designated a Center for Innovation in Advanced Development and Manufacturing (CIADM), with an ABEC 4,000L CSR bioreactor. The system will be custom designed to Emergent’s process needs, operational requirements, and facility constraints, and will greatly expand cell culture capacity at the Bayview site.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171024005257/en/

ABEC Custom Single Run (CSR®) Scalable Single-Use Solutions (Photo: Business Wire)

ABEC Custom Single Run (CSR®) Scalable Single-Use Solutions (Photo: Business Wire)

The 4,000L CSR is the largest single use bioreactor size available in the industry by a factor of two, resulting in approximately twice the productivity per floor space and lower cost of goods for cell culture-based biopharmaceuticals. The system can also deliver performance comparable to stainless steel systems and can be fully customized for different products, resulting in higher cell culture productivity and faster process transfer and scale-up.

Scott Battist, Emergent BioSolutions Vice President and General Manager of the Bayview site said, “The CIADM is designed to be a flexible, multi-product facility that cost-effectively addresses the diverse needs of our customers. ABEC’s CSR enables us to fully realize the benefits of single use technology by improving flexibility while leveraging economies of scale.”

“Emergent has been an ABEC customer for many years,” said Scott Pickering, ABEC President and CEO. “We are pleased that Emergent has chosen ABEC’s CSR technology to be part of their next-generation manufacturing strategy, and we look forward to continuing this long-term partnership.”

About ABEC

Since 1974, ABEC has been a leader in delivering integrated process solutions and services for manufacturing in the biopharmaceutical industry. A majority of the world’s pharmaceutical and biotech companies are ABEC customers with many of today’s leading therapies manufactured by processes and equipment engineered, manufactured, installed and serviced by ABEC. ABEC’s unique value is based on long experience, complete in-house capabilities, a custom, flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities ABEC’s turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. Visit: www.abec.com, www.abecsingleuse.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171024005257/en/

CONTACT

ABEC
Media Contact:
Susan Cooper Curcio, Director of Marketing
+1
610-861-4666
scurcio@abec.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda Announces Information Related to its Pending Voluntary and Conditional Public Takeover Bid for Outstanding Shares and American Depositary Shares of TiGenix
  • Prota/MCRI Completes Enrolment of Phase 2b Multicentre Clinical Trial of Probiotic Oral Immunotherapy for the Treatment of Peanut Allergy (PPOIT-003)
  • Dr. Reddy’s Q4 and FY18 Financial Results
  • 武田薬品が米国臨床腫瘍学会(ASCO)と欧州血液学会(EHA)の年次総会でオンコロジーの広範なポートフォリオとパイプラインのデータを発表
  • ResMed赞助的研究显示,采用居家吸氧与居家无创通气相结合治疗COPD具有成本效益